Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dystrophy care, targeting broader ages and mutations. We are witnessing the fastest pivot in rare-disease ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target from $5 to $6 while keeping a Market Outperform rating. The update ...

It uses a topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Astellas has significant expertise in ...

It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Astellas has significant ...